Importance of surrogate markers in evaluation of antiviral therapy for HIV infection

被引:13
作者
Deyton, L
机构
[1] Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1996年 / 276卷 / 02期
关键词
D O I
10.1001/jama.276.2.159
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:159 / 160
页数:2
相关论文
共 28 条
[1]   CD4+ LYMPHOCYTES ARE AN INCOMPLETE SURROGATE MARKER FOR CLINICAL PROGRESSION IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION TAKING ZIDOVUDINE [J].
CHOI, SS ;
LAGAKOS, SW ;
SCHOOLEY, RT ;
VOLBERDING, PA .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (09) :674-680
[2]   Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine [J].
Collier, AC ;
Coombs, RW ;
Schoenfeld, DA ;
Bassett, RL ;
Timpone, J ;
Baruch, A ;
Jones, M ;
Facey, K ;
Whitacre, C ;
McAuliffe, VJ ;
Friedman, HM ;
Merigan, TC ;
Reichman, RC ;
Hooper, C ;
Corey, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) :1011-1017
[3]   PLASMA VIREMIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTION [J].
COOMBS, RW ;
COLLIER, AC ;
ALLAIN, JP ;
NIKORA, B ;
LEUTHER, M ;
GJERSET, GF ;
COREY, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) :1626-1631
[4]  
DAQUILA RT, 1995, P 2 NAT C HUM RETR R
[5]   SERUM P24 ANTIGEN LEVEL AS AN INTERMEDIATE END-POINT IN CLINICAL-TRIALS OF ZIDOVUDINE IN PEOPLE INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
DEGRUTTOLA, V ;
BECKETT, LA ;
COOMBS, RW ;
ARDUINO, JM ;
BALFOUR, HH ;
RASHEED, S ;
HOLLINGER, FB ;
FISCHL, MA ;
VOLBERDING, P ;
GROUP, TACT .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (04) :713-721
[6]   RISK OF AIDS RELATED COMPLEX AND AIDS IN HOMOSEXUAL MEN WITH PERSISTENT HIV ANTIGENEMIA [J].
DEWOLF, F ;
GOUDSMIT, J ;
PAUL, DA ;
LANGE, JMA ;
HOOIJKAAS, C ;
SCHELLEKENS, P ;
COUTINHO, RA ;
VANDERNOORDAA, J .
BMJ-BRITISH MEDICAL JOURNAL, 1987, 295 (6598) :569-572
[7]   TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].
ERON, JJ ;
BENOIT, SL ;
JEMSEK, J ;
MACARTHUR, RD ;
SANTANA, J ;
QUINN, JB ;
KURITZKES, DR ;
FALLON, MA ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669
[8]   PREDICTIVE MARKERS FOR THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) IN HEMOPHILIACS - PERSISTENCE OF P24 ANTIGEN AND LOW T4 CELL COUNT [J].
EYSTER, ME ;
BALLARD, JO ;
GAIL, MH ;
DRUMMOND, JE ;
GOEDERT, JJ .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (12) :963-969
[9]   THE HUMAN IMMUNODEFICIENCY VIRUS - INFECTIVITY AND MECHANISMS OF PATHOGENESIS [J].
FAUCI, AS .
SCIENCE, 1988, 239 (4840) :617-622
[10]   SURROGATE AND AUXILIARY END-POINTS IN CLINICAL-TRIALS, WITH POTENTIAL APPLICATIONS IN CANCER AND AIDS RESEARCH [J].
FLEMING, TR ;
PRENTICE, RL ;
PEPE, MS ;
GLIDDEN, D .
STATISTICS IN MEDICINE, 1994, 13 (09) :955-968